SG301

Phase 2Small molecule

HHangzhou Sumgen Biotech Co., Ltd.

SG301 is one of 41 small molecule programs targeting Primary Immune Thrombocytopenia. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Immune ThrombocytopeniaRecruiting

Relapsed or Refractory Multiple MyelomaActive, not recruiting

Systemic Lupus Erythematosus (SLE)Recruiting

Nephrotic SyndromeRecruiting

Primary Immune ThrombocytopeniaPhase 2

Recruiting

Relapsed or Refractory Multiple MyelomaPhase 1

Active, not recruiting

Systemic Lupus Erythematosus (SLE)Phase 2

Recruiting

Nephrotic SyndromePhase 2

Recruiting

Competition

Competitive Landscape

30 competitors in Nephrotic Syndrome

#DrugCompanyPhaseTrials

Rituxan

Roche

Approved

15 2

Cellcept

Roche

Approved

7 3

Farxiga

AstraZeneca

Approved

3 4

Neoral

Novartis

Approved

2 5

Lovenox

Sanofi

Approved

1 6

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

4 7

Thalitone

Rayos

4 9

Aldactone

Pfizer

Approved

—10

Bumex

VValidus Pharmaceuticals

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 1Active, not recruiting

Relapsed or Refractory Multiple Myeloma

NCT04684108

Q2 2027

Phase 2Recruiting

Primary Immune Thrombocytopenia

NCT07710248

Q4 2027

Phase 2Recruiting

Systemic Lupus Erythematosus (SLE)

NCT07447986

Q1 2028

Phase 3Recruiting

Relapsed/refractory Multiple Myeloma

NCT06508983

Clinical

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)2 trials

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Efficacy and Safety of SG301 SC Injection in Patients With Systemic Lupus Erythematosus

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 2·NCT07447986·120 enrolled

A Randomized, Double-blind, Placebo-controlled Phase 1 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Characteristics of SG301 SC Injection in Single-dose Healthy Subjects and Multiple-dose Systemic Lupus Erythematosus (SLE) Subjects

Completed·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT06144710·48 enrolled

Nephrotic Syndrome1 trial

A Study of Anti-CD38 Monoclonal Antibody (SG301) Subcutaneous Injection in Children With Nephrotic Syndrome With Frequent Relapses or Steroid Dependence

Recruiting·MMao Jianhua·Phase 2·NCT07087314·30 enrolled

Primary Immune Thrombocytopenia1 trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study to Evaluate the Safety and Efficacy of SG301 SC Injection in Patients With Primary Immune Thrombocytopenia

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 2·NCT07710248·60 enrolled

Relapsed or Refractory Multiple Myeloma1 trial

A Phase 1 Study of SG301 in Subjects With Hematological Malignancies

Active, not recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 1·NCT04684108·61 enrolled

Relapsed/Refractory Multiple Myeloma1 trial

A Phase 3 Randomized, Placebo-controlled, Double-blind, Multicenter Study Comparing SG301 in Combination With Pomalidomide and Dexamethasone Versus Placebo in Combination With Pomalidomide and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Recruiting·HHangzhou Sumgen Biotech Co., Ltd.·Phase 3·NCT06508983·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for SG301. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SG301 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SG301. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Hangzhou Sumgen Biotech Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: HHangzhou Sumgen Biotech Co., Ltd.

SG301

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Q1 2028

Trials by Indication[1]

Systemic Lupus Erythematosus (SLE)2 trials

Nephrotic Syndrome1 trial

Primary Immune Thrombocytopenia1 trial

Relapsed or Refractory Multiple Myeloma1 trial

Relapsed/Refractory Multiple Myeloma1 trial

References

Drug Info

Quick Facts

Related News